Figure 4.
![Transient inhibition of RUNX1 proteolytic degradation during megakaryocytic differentiation of RUNX1-FPD iPSCs. (A) In vitro iPSC megakaryocyte differentiation with drug treatment. (B) Representative flow diagrams of iPSC-derived megakaryocyte progenitors (CD41a+/CD45−). (C) Relative fold change of megakaryocyte progenitors generated from in vitro iPSC differentiation (FPD-iPSCs [n = 3]; isogenic and wild-type N-2.12 control cells [n = 2]). (D) Scored iPSC-derived megakaryocyte colonies after 14 days of a CFU assay. Error bars show standard deviation. *P < .05, using a 2-tailed Student t test assuming unequal variance.](https://ash.silverchair-cdn.com/ash/content_public/journal/bloodadvances/5/3/10.1182_bloodadvances.2020002709/2/advancesadv2020002709f4.png?Expires=1730500647&Signature=lAehsvktNPvxAiVnrluodpZdGl0tzxDuAVjwEZYe2nQNPPphlnO3MsiQtXqMMXtNfQgrgo2Ak6iKO11Fc1INym4NapHTebIRTJPC0sHT8JrXs54E7JRkR7eBl4KWQzCyl6m7GyhTJSHZKYbbYSgWYCDi~vSgXF1JJ70r3pZLCBdmlVgcatAnmT-OLLr~53kG8IlKbEja3WU394niYgiOXPDY7-3-R2jLKou3dJeM9XeIL2ks5jjBvvJZAqTcFCxFpzyoWIC-WrwgJOp1cD2rA3EyXcK2uXDUz1VF9qs4rqi6bFKKOs8BM6JKzgs6c4bX7I54UNg9fWqJ9Q1CKK7Lxw__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
Transient inhibition of RUNX1 proteolytic degradation during megakaryocytic differentiation of RUNX1-FPD iPSCs. (A) In vitro iPSC megakaryocyte differentiation with drug treatment. (B) Representative flow diagrams of iPSC-derived megakaryocyte progenitors (CD41a+/CD45−). (C) Relative fold change of megakaryocyte progenitors generated from in vitro iPSC differentiation (FPD-iPSCs [n = 3]; isogenic and wild-type N-2.12 control cells [n = 2]). (D) Scored iPSC-derived megakaryocyte colonies after 14 days of a CFU assay. Error bars show standard deviation. *P < .05, using a 2-tailed Student t test assuming unequal variance.